世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

欧州のアトピー性皮膚炎治療薬市場予測 2019-2027年

EUROPE ATOPIC DERMATITIS DRUGS MARKET FORECAST 2019-2027

 

出版社 出版年月電子版価格 ページ数
Inkwood Research
インクウッドリサーチ
2018年10月US$1,250
シングルユーザ(印刷不可PDF)
72

サマリー

この調査レポートは欧州のアトピー性皮膚炎治療薬市場を分析・予測したInkwood Researchの市場調査報告書です。

Description

KEY FINDINGS

Experts have estimated that a high number of people belonging to the European population suffer from conditions such as conjunctivitis, skin allergies and food allergies. The market for atopic dermatitis drugs in Europe is, therefore expected to showcase a CAGR of 3.30% over the forecast period of 2019-2027.

MARKET INSIGHTS

Researchers have suggested that with the growing prices of the latest medications and increasing number of patients, the dependence on these medicines and drugs to treat symptoms is expected to increase. One of the fastest growing markets for atopic dermatitis drugs in the European market is Russia. According to forecasts, the country is expected to have the highest CAGR by 2027. The most probable reason for this might be poor hygienic conditions and heavy industrialization in the area.

COMPETITIVE INSIGHTS


Leading market players include Aqua Pharmaceuticals (An Almirall Company), Allergan Plc, Astellas Pharma Inc., Biofrontera Ag, Bayer Ag, Bristol-Myers Squibb, Encore Dermatology, Stiefel Laboratories, Inc, Galderma Sa, Meda Pharmaceuticals (Mylan N.V.), Leo Pharma,Novartis Ag, Regeneron Pharmaceuticals, Pfizer, Valent Pharmaceutical Inc and Sanofi Sa.



目次

Table of Contents

1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP-DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. TOPICAL ROUTE OF ADMINISTRATION HOLDS MAJORITY OF THE OVERALL MARKET SHARE
3.2.2. INTERLEUKIN INHIBITOR MARKET IS ANTICIPATED TO GENERATE HIGHEST REVENUE
4. MARKET DETERMINANTS
4.1. MARKET DRIVERS
4.1.1. GROWING PREVALENCE OF FOOD ALLERGIES EXACERBATING ATOPIC DERMATITIS
4.1.2. GROWING FOCUS ON SYSTEMATIC THERAPIES
4.1.3. INCREASING USE OF PHARMACOLOGICAL PRODUCTS IN DEVELOPING COUNTRIES
4.2. MARKET RESTRAINTS
4.2.1. STRINGENT REGULATIONS FOR PRODUCT APPROVAL
4.2.2. GENERIC COMPETITION
4.3. MARKET OPPORTUNITIES
4.3.1. INCREASING M&A LEADING TO MARKET CONSOLIDATION
4.3.2. LAUNCH OF FIRST BIOLOGIC FOR ATOPIC DERMATITIS
4.3.3. GROWING FOCUS ON NOVEL DRUGS
4.4. MARKET CHALLENGES
4.4.1. BLACK BOX WARNING FOR ELIDEL AND PROTOPIC
4.4.2. HIGHLY GENERICIZED MARKET
4.4.3. POOR PATIENT ADHERENCE DUE TO INADEQUATE INFORMATION ON DRUG USAGE
5. MARKET SEGMENTATION
5.1. MARKET BY ROUTE OF ADMINISTRATION (ROA) 2019-2027
5.1.1. TOPICAL
5.1.2. ORAL
5.1.3. INJECTIBLES
5.2. MARKET BY DRUG CLASS 2019-2027
5.2.1. TOPICAL ANTIBIOTICS
5.2.2. TOPICAL ANTIHISTAMINES
5.2.3. TOPICAL CORTICOSTEROIDS
5.2.4. TOPICAL MOISTURIZERS/EMOLLIENTS
5.2.5. TOPICAL CALCINEURIN INHIBITORS
5.2.6. IMMUNOMODULATORS
5.2.7. OFF-LABEL THERAPIES
5.2.8. SYSTEMIC AGENTS
5.2.9. PDE4 INHIBITOR
5.2.10. INTERLEUKIN INHIBITOR
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCES ANALYSIS
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTE
6.1.3. BARGAINING POWER OF SUPPLIERS
6.1.4. BARGAINING POWER OF BUYERS
6.1.5. THREAT OF COMPETITIVE RIVALRY
6.2. OPPORTUNITY MATRIX
6.3. PIPELINE ANALYSIS
6.4. LEGAL, POLICY AND REGULATORY ISSUES
7. GEOGRAPHICAL ANALYSIS
7.1. EUROPE
7.1.1. GERMANY
7.1.2. FRANCE
7.1.3. THE UNITED KINGDOM
7.1.4. RUSSIA
7.1.5. ITALY
7.1.6. REST OF EUROPE
8. COMPANY PROFILES
8.1. ALLERGAN PLC
8.1.1. COMPANY OVERVIEW
8.1.2. PRODUCT PORTFOLIO
8.1.3. SWOT ANALYSIS
8.1.4. STRATEGIC INITIATIVES
8.2. AQUA PHARMACEUTICALS (AN ALMIRALL COMPANY)
8.2.1. COMPANY OVERVIEW
8.2.2. PRODUCT PORTFOLIO
8.2.3. SWOT ANALYSIS
8.3. ASTELLAS PHARMA INC.
8.3.1. COMPANY OVERVIEW
8.3.2. PRODUCT PORTFOLIO
8.3.3. SWOT ANALYSIS
8.3.4. STRATEGIC INITIATIVES
8.4. BAYER AG
8.4.1. COMPANY OVERVIEW
8.4.2. PRODUCT PORTFOLIO
8.4.3. SWOT ANALYSIS
8.4.4. STRATEGIC INITIATIVES
8.5. BIOFRONTERA AG
8.5.1. COMPANY OVERVIEW
8.5.2. PRODUCT PORTFOLIO
8.5.3. SWOT ANALYSIS
8.6. BRISTOL-MYERS SQUIBB
8.6.1. COMPANY OVERVIEW
8.6.2. PRODUCT PORTFOLIO
8.6.3. SWOT ANALYSIS
8.7. STIEFEL LABORATORIES, INC
8.7.1. COMPANY OVERVIEW
8.7.2. PRODUCT PORTFOLIO
8.7.3. SWOT ANALYSIS
8.8. ENCORE DERMATOLOGY
8.8.1. COMPANY OVERVIEW
8.8.2. PRODUCT PORTFOLIO
8.8.3. SWOT ANALYSIS
8.8.4. STRATEGIC INITIATIVES
8.9. GALDERMA SA
8.9.1. COMPANY OVERVIEW
8.9.2. PRODUCT PORTFOLIO
8.9.3. SWOT ANALYSIS
8.9.4. STRATEGIC INITIATIVES
8.10. LEO PHARMA
8.10.1. COMPANY OVERVIEW
8.10.2. PRODUCT PORTFOLIO
8.10.3. SWOT ANALYSIS
8.10.4. STRATEGIC INITIATIVES
8.11. MEDA PHARMACEUTICALS (MYLAN N.V.)
8.11.1. COMPANY OVERVIEW
8.11.2. PRODUCT PORTFOLIO
8.11.3. SWOT ANALYSIS
8.11.4. STRATEGIC INITIATIVES
8.12. NOVARTIS AG
8.12.1. COMPANY OVERVIEW
8.12.2. PRODUCT PORTFOLIO
8.12.3. SWOT ANALYSIS
8.12.4. STRATEGIC INITIATIVES
8.13. PFIZER
8.13.1. COMPANY OVERVIEW
8.13.2. PRODUCT PORTFOLIO
8.13.3. SWOT ANALYSIS
8.13.4. STRATEGIC INITIATIVES
8.14. REGENERON PHARMACEUTICALS
8.14.1. COMPANY OVERVIEW
8.14.2. PRODUCT PORTFOLIO
8.14.3. SWOT ANALYSIS
8.14.4. STRATEGIC INITIATIVES
8.15. SANOFI SA
8.15.1. COMPANY OVERVIEW
8.15.2. PRODUCT PORTFOLIO
8.15.3. SWOT ANALYSIS
8.15.4. STRATEGIC INITIATIVES
8.16. VALENT PHARMACEUTICAL INC.
8.16.1. COMPANY OVERVIEW
8.16.2. PRODUCT PORTFOLIO
8.16.3. SWOT ANALYSIS

TABLE LIST
TABLE 1 EUROPE ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
TABLE 2 RECENT MERGERS AND ACQUISITIONS IN ATOPIC DERMATITIS DRUGS MARKET
TABLE 3 EUROPE ATOPIC DERMATITIS DRUGS MARKET BY ROA 2019-2027 ($ MILLION)
TABLE 4 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL ROA 2019-2027 ($ MILLION)
TABLE 5 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN ORAL ROA 2019-2027 ($ MILLION)
TABLE 6 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN INJECTIBLES ROA 2019-2027 ($ MILLION)
TABLE 7 EUROPE ATOPIC DERMATITIS DRUGS MARKET BY DRUG CLASS 2019-2027 ($ MILLION)
TABLE 8 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL ANTIBIOTICS 2019-2027 ($ MILLION)
TABLE 9 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL ANTIHISTAMINES 2019-2027 ($ MILLION)
TABLE 10 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL CORTICOSTEROIDS 2019-2027 ($ MILLION)
TABLE 11 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL MOISTURIZERS/EMOLLIENTS 2019-2027 ($ MILLION)
TABLE 12 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL CALCINEURIN INHIBITORS 2019-2027 ($ MILLION)
TABLE 13 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN IMMUNOMODULATORS 2019-2027 ($ MILLION)
TABLE 14 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN OFF-LABEL THERAPIES 2019-2027 ($ MILLION)
TABLE 15 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN SYSTEMIC AGENTS 2019-2027 ($ MILLION)
TABLE 16 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN PDE4 INHIBITOR 2019-2027 ($ MILLION)
TABLE 17 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN INTERLEUKIN INHIBITOR 2019-2027 ($ MILLION)
TABLE 18 PIPELINE PORTFOLIO OF DIABETES DRUGS MARKET
TABLE 19 REGULATORY FRAMEWORK IN ATOPIC DERMATITIS MARKET
TABLE 20 EUROPE ATOPIC DERMATITIS DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)


FIGURES LIST
FIGURE 1 EUROPE ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 2 GERMANY ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 3 FRANCE ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 4 THE UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 5 RUSSIA ATOPIC DERMATITIS DRUGS MARKET, 2019-2027 ($ MILLION)
FIGURE 6 ITALY ATOPIC DERMATITIS DRUGS MARKET, 2019-2027 ($ MILLION)
FIGURE 7 REST OF EUROPE ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)

List of Tables

TABLE LIST
TABLE 1 EUROPE ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
TABLE 2 RECENT MERGERS AND ACQUISITIONS IN ATOPIC DERMATITIS DRUGS MARKET
TABLE 3 EUROPE ATOPIC DERMATITIS DRUGS MARKET BY ROA 2019-2027 ($ MILLION)
TABLE 4 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL ROA 2019-2027 ($ MILLION)
TABLE 5 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN ORAL ROA 2019-2027 ($ MILLION)
TABLE 6 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN INJECTIBLES ROA 2019-2027 ($ MILLION)
TABLE 7 EUROPE ATOPIC DERMATITIS DRUGS MARKET BY DRUG CLASS 2019-2027 ($ MILLION)
TABLE 8 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL ANTIBIOTICS 2019-2027 ($ MILLION)
TABLE 9 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL ANTIHISTAMINES 2019-2027 ($ MILLION)
TABLE 10 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL CORTICOSTEROIDS 2019-2027 ($ MILLION)
TABLE 11 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL MOISTURIZERS/EMOLLIENTS 2019-2027 ($ MILLION)
TABLE 12 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL CALCINEURIN INHIBITORS 2019-2027 ($ MILLION)
TABLE 13 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN IMMUNOMODULATORS 2019-2027 ($ MILLION)
TABLE 14 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN OFF-LABEL THERAPIES 2019-2027 ($ MILLION)
TABLE 15 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN SYSTEMIC AGENTS 2019-2027 ($ MILLION)
TABLE 16 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN PDE4 INHIBITOR 2019-2027 ($ MILLION)
TABLE 17 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN INTERLEUKIN INHIBITOR 2019-2027 ($ MILLION)
TABLE 18 PIPELINE PORTFOLIO OF DIABETES DRUGS MARKET
TABLE 19 REGULATORY FRAMEWORK IN ATOPIC DERMATITIS MARKET
TABLE 20 EUROPE ATOPIC DERMATITIS DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)

Companies Mentioned

1. ALLERGAN PLC
2. AQUA PHARMACEUTICALS (AN ALMIRALL COMPANY)
3. ASTELLAS PHARMA INC.
4. BAYER AG
5. BIOFRONTERA AG
6. BRISTOL-MYERS SQUIBB
7. STIEFEL LABORATORIES, INC
8. ENCORE DERMATOLOGY
9. GALDERMA SA
10. LEO PHARMA
11. MEDA PHARMACEUTICALS (MYLAN N.V.)
12. NOVARTIS AG
13. PFIZER
14. REGENERON PHARMACEUTICALS
15. SANOFI SA
16. VALENT PHARMACEUTICAL INC.

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る